出处
《放射学实践》
2004年第11期850-852,共3页
Radiologic Practice
基金
国家自然科学基金资助项目 (30 1 71 0 62 )
参考文献14
-
1Zamora PO,Guhlke S,Bender H,et al. Experimental radiotherapy of receptor-positive human prostate adenocarcinoma with 188Re-RC-160, a directly radiolabeled somatostatin analogue[J]. Int J Cancer, 1996,65(2) :214-220.
-
2Lister-James J,Knight LC,Maurer AH, et al. Thrombus imaging with a technetiurn-99m-labeled, activated platelet receptorbinding peptide[J]. J Nucl Med, 1996,37(5): 775-781.
-
3Liu S,Edwards DS. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals[J]. Chem Rev, 1999,99(9): 2235-2268.
-
4Meares CF. Chelating agents for the biding of metals to antibodies [J]. Nucl Med Biol, 1986,13(4) :311-318.
-
5Geoghegan KF, Stroh JG. Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modofocation at N-terminal serine[J].Bioconjugate Chem, 1992,3(2): 138-146.
-
6Pearson DA, Lister-James J, McBride WJ, et al. Somatostatin receptor-binding peptides labeled with technetium-99m: chemistry and initial biological studies [J ]. J Med Chem, 1996,39 ( 7 ): 1361-1371.
-
7Arano Y,Akizawa H,Uezono T,et al. Conventional and high-yield synthesis of DTPA conjugated peptides: application of a monoreactive DTPA to DTPA-D-Phe1-octreotide synthesis[J]. Bioconjugate Chem, 1997,8(3): 442-446.
-
8Bakker WH, Albert R, Bruns C, et al. (111In-DTPA-D-Phe)-octreotide,a potential radiopharmaceutical for imaging of somatostatin receptorpositive tumors: synthesis, radiolabeling and in vitro validation[J]. Life Sci, 1991,49(22): 1583-1591.
-
9de Jong M,Bakker WH,Krenning EP,et al. Yttrium-90 and indium-111 labeling,receptor binding and biodistribution of (DOTA0,D-Phe1,Tyr3) octreotide, a promising somatostatin analogue for radionuclide therapy[J]. Eur J Nucl Med, 1997,24(4): 368-371.
-
10Bangard M,Behe M,Guhlke S,et al. Detection of somatostatin receptor-positive tumours using the new 99m-Tctricine- HYNIC-d-Phe1-Tyr3-octreotide:first results in patients and comparison with 111In-DTPA-d-Phe1-octreotide[J]. Eur J Nucl Med,2000,27 (6): 628-637.
同被引文献56
-
1徐贤坤,王霜,曾宪垠,汪淑芳.聚乙二醇化重组人白细胞介素6的放射性标记[J].核农学报,2006,20(3):236-240. 被引量：1
-
2魏莉,罗荣城.放射性核素标记抗CD20单克隆抗体治疗B细胞淋巴瘤的研究进展[J].国际放射医学核医学杂志,2006,30(3):153-157. 被引量：5
-
3Labroo V M, Hebel D, Kirk K L, et al. Int J Pept Protein Res, 1991, 37:430-439
-
4Ogawa M, Hatano K, Oishi S, et al. Nucl Med Biol, 2003, 30:1-9
-
5Schirrmacher R, Bradtmoller G, Schirrmacher E, et al. Angew Chem Int Ed, 2006, 45:6047-6050
-
6Schirrmacher E, Wangler B, Cypryk M, et al. Bioconjugate Chem, 2007, 18:2085-2089
-
7Rennen H J, Laverman P, Van Eerd J E, et al. Nucl Med Biol, 2007, 34:691-695
-
8Lee Y S, Jeong J M, Kim H W, et al. Nucl Med Biol, 2006, 33:677-683
-
9Bruus-Jensen K, Poethko T, Schottelius M, et al. Nucl Med Biol, 2006, 33:173-183
-
10Jelinski M, Hamacher K, Coenen H H. J Label Compd Radiopharm, 2002, 45:217-229
二级引证文献2
-
1胡孔珍,王红亮,唐刚华.^(18)F标记多肽方法研究进展[J].同位素,2012,25(4):243-252. 被引量：2
-
2温凯,陈宝军,郭飞虎,梁积新,殷胤,陈大明,崔海平.点击化学法制备奥曲肽类似物^(18)F-Ta-Gluc-TOCA及其生物学评价[J].同位素,2013,26(2):91-97. 被引量：2
-
1胡继岳,濮恒学,樊一桥.立体化学中构型的标记方法[J].镇江医学院学报,1994,4(2):82-83.
-
2程秋雁.蛋白质和多肽的放射性标记方法研究进展[J].实用临床医药杂志,2010,14(8):165-167.
-
3追踪癌细胞显像剂问世[J].临床荟萃,2009,24(7):608-608.
-
4科学家研制出可追踪癌细胞的显像剂[J].家庭用药,2009(1):6-6.
-
5李平安,李国庆,申斌,黄建军,郭云波.X线照片标记技术的现状与展望[J].中国医疗器械杂志,2001,25(6):355-356. 被引量：2
-
6李晔,王学斌.放射性标记的维生素B12及其衍生物在肿瘤诊治中的应用进展[J].国外医学（放射医学核医学分册）,2003,27(6):255-259.
-
7日美科学家研制出可追踪癌细胞的显像剂[J].求医问药,2009(11):55-55.
-
8卢作勇.放射性标记肽—新一类成像剂[J].中国医药情报,1995,1(2):112-116.
-
9汪新柱,陈晓飞,周晟,贾有福.MARK标记技术在X线摄影中的应用价值[J].中国临床研究,2012,25(10):1011-1011. 被引量：1
-
10张城,杨日芳.稳定同位素在药代动力学中的应用[J].国外医学（药学分册）,2000,27(1):32-35. 被引量：3
